This expansion study of ADIPemCis at the RP2D confirmed good safety and a high rate of disease control and partial response (~50%) in patients with ASS1‐deficient non‐squamous NSCLC consistent with the dose‐escalation study.19 This evidence concerns the gene ASS1 and non-small cell lung carcinoma.